Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Undersea Hyperb Med ; 51(2): 145-157, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38985151

RESUMO

Introduction: Increasing cancer survivorship, in part due to new radiation treatments, has created a larger population at risk for delayed complications of treatment. Radiation cystitis continues to occur despite targeted radiation techniques. Materials and Methods: To investigate value-based care applying hyperbaric oxygen (HBO2) to treat delayed radiation cystitis, we reviewed public-access Medicare data from 3,309 patients from Oct 1, 2014, through Dec 31, 2019. Using novel statistical modeling, we compared cost and clinical effectiveness in a hyperbaric oxygen group to a control group receiving conventional therapies. Results: Treatment in the hyperbaric group provided a 36% reduction in urinary bleeding, a 78% reduced frequency of blood transfusion for hematuria, a 31% reduction in endoscopic procedures, and fewer hospitalizations when study patients were compared to control. There was a 53% reduction in mortality and reduced unadjusted Medicare costs of $5,059 per patient within the first year after completion of HBO2 treatment per patient. When at least 40 treatments were provided, cost savings per patient increased to $11,548 for the HBO2 study group compared to the control group. This represents a 37% reduction in Medicare spending for the HBO2-treated group. We also validate a dose-response curve effect with a complete course of 40 or more HBO2 treatments having better clinical outcomes than those treated with fewer treatments. Conclusion: These data support previous studies that demonstrate clinical benefits now with cost- effectiveness when adjunctive HBO2 treatments are added to routine interventions. The methodology provides a comparative group selected without bias. It also provides validation of statistical modeling techniques that may be valuable in future analysis, complementary to more traditional methods.


Assuntos
Análise Custo-Benefício , Cistite , Oxigenoterapia Hiperbárica , Medicare , Lesões por Radiação , Oxigenoterapia Hiperbárica/economia , Oxigenoterapia Hiperbárica/métodos , Humanos , Cistite/terapia , Cistite/economia , Medicare/economia , Estados Unidos , Lesões por Radiação/terapia , Lesões por Radiação/economia , Feminino , Masculino , Idoso , Redução de Custos , Hematúria/etiologia , Hematúria/terapia , Hematúria/economia , Hospitalização/economia , Transfusão de Sangue/economia , Transfusão de Sangue/estatística & dados numéricos , Centers for Medicare and Medicaid Services, U.S. , Idoso de 80 Anos ou mais
2.
Undersea Hyperb Med ; 48(1): 1-12, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33648028

RESUMO

The SARS-Cov-2 (COVID-19) pandemic remains a major worldwide public health issue. Initially, improved supportive and anti-inflammatory intervention, often employing known drugs or technologies, provided measurable improvement in management. We have recently seen advances in specific therapeutic interventions and in vaccines. Nevertheless, it will be months before most of the world's population can be vaccinated to achieve herd immunity. In the interim, hyperbaric oxygen (HBO2) treatment offers several potentially beneficial therapeutic effects. Three small published series, one with a propensity-score-matched control group, have demonstrated safety and initial efficacy. Additional anecdotal reports are consistent with these publications. HBO2 delivers oxygen in extreme conditions of hypoxemia and tissue hypoxia, even in the presence of lung pathology. It provides anti-inflammatory and anti-proinflammatory effects likely to ameliorate the overexuberant immune response common to COVID-19. Unlike steroids, it exerts these effects without immune suppression. One study suggests HBO2 may reduce the hypercoagulability seen in COVID patients. Also, hyperbaric oxygen offers a likely successful intervention to address the oxygen debt expected to arise from a prolonged period of hypoxemia and tissue hypoxia. To date, 11 studies designed to investigate the impact of HBO2 on patients infected with SARS-Cov-2 have been posted on clinicaltrials.gov. This paper describes the promising physiologic and biochemical effects of hyperbaric oxygen in COVID-19 and potentially in other disorders with similar pathologic mechanisms.


Assuntos
COVID-19/terapia , Oxigenoterapia Hiperbárica/métodos , COVID-19/sangue , COVID-19/complicações , COVID-19/imunologia , Hipóxia Celular , Síndrome da Liberação de Citocina/imunologia , Citocinas/sangue , Humanos , Hipóxia/terapia , Inflamação/terapia , Células-Tronco Mesenquimais , Oxigênio/intoxicação , Consumo de Oxigênio , Trombofilia/etiologia , Trombofilia/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA